Monoclonal antibody to D-Dimer, clone 3B6

D-Dimer: released by fibrinolysis of FXIII cross-linked fibrin

100 µg 365 € available

Art. No. A046
Background info As the very last step of blood coagulation factor XIII (plasma transglutaminase) cross links D-domains of fibrin molecules. Clot degradation by the fibrinolytic protease plasmin then releases so called D-Dimers.
D-Dimers serve as marker for thrombotic events and the blood disease disseminated intravascular coagulation (DIC). It is an approved diagnostic marker for the exclusion of venous thromboembolism (VTE). There is growing evidence, that D-Dimer antitgen measurements may help clinicians in numerous other clinical scenarios like deep vein thrombosis (DVT), pulmonary embolism, hemolysis or even in chemotherapy (Adam et al., Blood 2009; 113:2878-87)
Host Mouse
Immunogen Human cross-linked D-Dimer
Specificity Specific for clot derived XL-FDPs (Cross-Linked Fibrin Degradation Products). Does not react with either fibrinogen or fibrinogen degradation products.
Appearance Single homogenous batch, 0.2 µM filtered supplied liquid in a 20 mM carbonate buffer, pH 9.2 containing 0.1% sodium azide.
Description >80% pure mouse monoclonal antibody (Isotype IgG3), purified by ammonium sulphate precipitation method.
Application Western blot, ELISA, Collodial Gold Lateral flow, Latex agglutination and Red Blood Cell Agglutination
Recommended as capture antibody with A047 in Sandwich Assays – Gold Conjugate lateral flow tests (detection antibody on nitrocellulose) and ELISA (Tag-HRP antibody)
Working dilutions Optimal dilutions should be determined by the end user- For Western-Blottin: 1 / 5,000 to 1 / 15,000 is a rough guideline
Storage Long term storage: < -60°C, Aliquotation is recommended in order to avoid repeated freeze thaw cycles.
Reference(s) Greenberg et al., Am. J. Clin. Pathol. 1987, 87:94-100
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.
  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland